Developer docs
API playgroundTry for free, no card

Search company profiles

ImmunoScape

Full company profile

uuid0000y3h

Namestring
ImmunoScape
Legal namestring
ImmunoScape Pte. Ltd.
Websiteurl
immunoscape.com
Company typeenum
Private
Founded yearint
2016
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSingapore, Singapore
HQ citystring
Singapore
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
TCR cell therapy, cancer immunotherapy, solid tumor therapy, immune profiling, TCR discovery
Industry2 codes
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAMAK
Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Cancer Immunotherapy
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1TCR-T Cell Therapy Development
TypeOne Time License
Description

Pre-revenue clinical-stage biotech developing TCR-based cancer immunotherapies. Revenue will be generated through eventual therapeutic product sales upon regulatory approval, along with potential milestone payments and royalties from licensing agreements.

immunoscape.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

ImmunoScape develops TCR-based cancer immunotherapies through its proprietary Seed-and-Boost platform, which combines engineered TCR-T cells with Immuno-STAT molecules to improve T cell expansion, persistence, and anti-tumor activity in solid tumors. The company's lead program, IS-001, targets WT1-positive solid tumors, and its Deep Immunomics technology underpins antigen and TCR discovery directly from patient-derived immune repertoires. ImmunoScape also extends its technology into partnered programs with pharmaceutical companies, including the CUE-100 series (CUE-102) with Cue Biopharma.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 100% survival in high tumor burden ovarian cancer model in preclinical studies
+1 more record
Product overview1 text field

ImmunoScape is a clinical-stage biotechnology company developing next-generation TCR-based cancer immunotherapies through its integrated platform approach. The company's core offering is the Seed and Boost™ Platform, which combines two key components: (1) IS-001, the lead program using WT1 TCR-T cells engineered via the Deep Immunomics Platform, and (2) CUE-102, a clinically validated Immuno-STAT® molecule (from the CUE-100 Series licensed from Cue Biopharma) that selectively expands and activates tumor-specific T-cells in-vivo. The Deep Immunomics Platform enables high-throughput discovery of potent TCRs, while the Immuno-STAT Platform provides the booster molecule technology for selective T-cell engagement and expansion. Additional offerings include the Cytographer® cloud-based bioinformatics platform for immune profiling data analysis.

Product and service2 records
1IS-001
CategoryCancer immunotherapy (TCR-T cell therapy)
Description

IS-001 is ImmunoScape's lead TCR-T cell therapy candidate, designed to treat WT1-positive solid tumors by leveraging the company's Seed-and-Boost strategy to improve T cell expansion, persistence, and anti-tumor activity. It is intended for cancer patients with WT1-expressing solid tumors who have limited treatment options.

2CUE-100 Series (including CUE-102)
CategoryImmuno-oncology (Immuno-STAT biologics)
Description

The CUE-100 series comprises Cue Biopharma's Immuno-STAT molecules co-developed with ImmunoScape, including CUE-102, designed to modulate T cell function against cancer. These programs represent the commercial application of ImmunoScape's Immuno-STAT technology in partnership with Cue Biopharma.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-04
Description

MOU to launch investigator-initiated clinical trial targeting WT1-positive solid tumors including ovarian, mesothelioma, pancreatic, and colorectal cancers. First patient dosing expected by September 2026.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-04
Description

Exclusive collaboration and license agreement to advance novel Seed-and-Boost immunotherapy combining Cue Biopharma's Immuno-STAT (CUE-100 series) with ImmunoScape's proprietary TCRs. Cue Biopharma received $15 million upfront payment ($10M in Q4 2025, $5M in November 2026) plus a 40% equity stake in ImmunoScape. The partnership targets solid tumor cell therapy with IND-enabling studies on track for 2027 submission.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-18
Description

G-Rex Grant of $250,000 to support WT1-targeted TCR-T cell therapy development including process development, quality control, and IND-enabling studies with goal of FDA submission in 2026. Grant aided by Wilson Wolf Manufacturing and Bio-Techne.

4Singapore Experimental Drug Development Centre (EDDC)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-01
Description

Strategic alliance formed in December 2023 to develop TCR-based bispecific molecules for solid tumors.

openpr.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage TCR-T cell therapy company with an FDA-approved solid tumor product (afami-cel for synovial sarcoma) and an MAGE-A4 franchise. Directly comparable to ImmunoScape as a TCR-T developer targeting solid tumor antigens with engineered T-cell receptors.

TypeDirect peer
Description

Clinical-stage TCR-based immunotherapy company developing engineered TCR-T cells (ACTengine) and TCR bispecifics against tumor-specific antigens including PRAME and MAGEA4/8, partnered with Bristol Myers Squibb. Directly comparable to ImmunoScape's TCR discovery + cell therapy platform approach.

TypeDirect peer
Description

Developer of the Immuno-STAT platform (CUE-100 series) that ImmunoScape has exclusively in-licensed for oncology. Cue holds 40% of ImmunoScape and shares the Seed-and-Boost program, making it simultaneously a partner and the closest comparable platform peer.

TypeDirect peer
Description

Clinical-stage cell therapy company developing TCR-T and CAR-T therapies for solid tumors, including HPV-associated cancers. Comparable in stage, modality (engineered TCR-T), and Singapore/Asia origins — ImmunoScape's VP of Discovery previously held a leadership role at Tessa.

5Tmunity Therapeutics
TypeEmerging player
Description

Cell therapy developer focused on engineered T cells (CAR-T and TCR-T) for solid tumors and autoimmune disease, founded out of the University of Pennsylvania. Led by Usman Azam (also on ImmunoScape's board) until its wind-down, making it a directly comparable TCR-T solid tumor play.

TypeEmerging player
Description

Developed TRuC-T cell therapies targeting solid tumors using a novel TCR fusion construct. Directly comparable modality (engineered T-cell receptor therapy for solid tumors) and recently combined with Adaptimmune, the leading direct peer.

TypeBroad incumbent
Description

Commercial-stage leader in cell therapy with approved CAR-T products (Yescarta, Tecartus) for hematologic malignancies. A broad incumbent in the engineered T-cell therapy space; Adrian Bot (now on ImmunoScape's board) previously served as Kite's CSO, providing direct strategic adjacency.

TypeBroad incumbent
Description

Delivered the first FDA-approved CAR-T therapy (Kymriah) and operates a major Cell and Gene Therapies unit previously headed by Usman Azam, who now sits on ImmunoScape's board. A broad incumbent with the most established cell therapy commercial infrastructure.

9Bristol Myers Squibb
TypeBroad incumbent
Description

Developer of Yervoy and Opdivo (immuno-oncology checkpoint inhibitors) and a partner of Immatics for TCR-based therapies. Comparable as a large pharma incumbent pursuing TCR-based solid tumor strategies via partnership and acquisition.

TypeBroad incumbent
Description

Developer of Imfinzi (durvalumab), a checkpoint inhibitor broadly used across solid tumor indications. Rachel Humphrey, who led Imfinzi's clinical development, is now an ImmunoScape SAB member — making AstraZeneca a strategically adjacent incumbent in solid tumor immunotherapy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ImmunoScape

Cancer Immunotherapyimmunoscape.com

ImmunoScape firmographics

Firmographics
Name
ImmunoScape
Legal name
ImmunoScape Pte. Ltd.
Website
https://immunoscape.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

ImmunoScape industry classification

Industry
Product category
Cancer Immunotherapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAMAK
Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • TCR cell therapy
  • Cancer immunotherapy
  • Solid tumor therapy
  • Immune profiling
  • TCR discovery

Where ImmunoScape is headquartered

Location

Headquarters

HQ city
Singapore
HQ country
Singapore
HQ region
Asia

Offices2 records

Markets served

ImmunoScape business model

Business model
GTM type
B2B
Offering type
Services

Revenue model

  1. TCR-T Cell Therapy Development: Pre-revenue clinical-stage biotech developing TCR-based cancer immunotherapies. Revenue will be generated through eventual therapeutic product sales upon regulatory approval, along with potential milestone payments and royalties from licensing agreements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

ImmunoScape product offering

Product offering

Core offering

ImmunoScape develops TCR-based cancer immunotherapies through its proprietary Seed-and-Boost platform, which combines engineered TCR-T cells with Immuno-STAT molecules to improve T cell expansion, persistence, and anti-tumor activity in solid tumors. The company's lead program, IS-001, targets WT1-positive solid tumors, and its Deep Immunomics technology underpins antigen and TCR discovery directly from patient-derived immune repertoires. ImmunoScape also extends its technology into partnered programs with pharmaceutical companies, including the CUE-100 series (CUE-102) with Cue Biopharma.

Product overview

ImmunoScape is a clinical-stage biotechnology company developing next-generation TCR-based cancer immunotherapies through its integrated platform approach. The company's core offering is the Seed and Boost™ Platform, which combines two key components: (1) IS-001, the lead program using WT1 TCR-T cells engineered via the Deep Immunomics Platform, and (2) CUE-102, a clinically validated Immuno-STAT® molecule (from the CUE-100 Series licensed from Cue Biopharma) that selectively expands and activates tumor-specific T-cells in-vivo. The Deep Immunomics Platform enables high-throughput discovery of potent TCRs, while the Immuno-STAT Platform provides the booster molecule technology for selective T-cell engagement and expansion. Additional offerings include the Cytographer® cloud-based bioinformatics platform for immune profiling data analysis.

Differentiator

Problem solved

Functional benefit

Products and services

  • IS-001 IS-001 is ImmunoScape's lead TCR-T cell therapy candidate, designed to treat WT1-positive solid tumors by leveraging the company's Seed-and-Boost strategy to improve T cell expansion, persistence, and anti-tumor activity. It is intended for cancer patients with WT1-expressing solid tumors who have limited treatment options.
  • CUE-100 Series (including CUE-102) The CUE-100 series comprises Cue Biopharma's Immuno-STAT molecules co-developed with ImmunoScape, including CUE-102, designed to modulate T cell function against cancer. These programs represent the commercial application of ImmunoScape's Immuno-STAT technology in partnership with Cue Biopharma.

Quantifiable outcome

  • 100% survival in high tumor burden ovarian cancer model in preclinical studies
  • +1 more outcomes

Companies that use ImmunoScape

Customer profile

Segments1 record

Ideal customer profiles2 records

ImmunoScape technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

ImmunoScape partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • NCI-Designated Comprehensive Cancer Center (U.S.)coreStrategic or Co-development Partner · 4 March 2026MOU to launch investigator-initiated clinical trial targeting WT1-positive solid tumors including ovarian, mesothelioma, pancreatic, and colorectal cancers. First patient dosing expected by September 2026.
  • Cue BiopharmacoreStrategic or Co-development Partner · 4 November 2025Exclusive collaboration and license agreement to advance novel Seed-and-Boost immunotherapy combining Cue Biopharma's Immuno-STAT (CUE-100 series) with ImmunoScape's proprietary TCRs. Cue Biopharma received $15 million upfront payment ($10M in Q4 2025, $5M in November 2026) plus a 40% equity stake in ImmunoScape. The partnership targets solid tumor cell therapy with IND-enabling studies on track for 2027 submission.
  • ScaleReadycoreStrategic or Co-development Partner · 18 September 2024G-Rex Grant of $250,000 to support WT1-targeted TCR-T cell therapy development including process development, quality control, and IND-enabling studies with goal of FDA submission in 2026. Grant aided by Wilson Wolf Manufacturing and Bio-Techne.
  • Singapore Experimental Drug Development Centre (EDDC)coreStrategic or Co-development Partner · 1 December 2023Strategic alliance formed in December 2023 to develop TCR-based bispecific molecules for solid tumors.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

ImmunoScape competitors and assessment

Company assessment

Direct peers

  • Adaptimmune: Clinical-stage TCR-T cell therapy company with an FDA-approved solid tumor product (afami-cel for synovial sarcoma) and an MAGE-A4 franchise. Directly comparable to ImmunoScape as a TCR-T developer targeting solid tumor antigens with engineered T-cell receptors.
  • Immatics: Clinical-stage TCR-based immunotherapy company developing engineered TCR-T cells (ACTengine) and TCR bispecifics against tumor-specific antigens including PRAME and MAGEA4/8, partnered with Bristol Myers Squibb. Directly comparable to ImmunoScape's TCR discovery + cell therapy platform approach.
  • Cue Biopharma: Developer of the Immuno-STAT platform (CUE-100 series) that ImmunoScape has exclusively in-licensed for oncology. Cue holds 40% of ImmunoScape and shares the Seed-and-Boost program, making it simultaneously a partner and the closest comparable platform peer.
  • Tessa Therapeutics: Clinical-stage cell therapy company developing TCR-T and CAR-T therapies for solid tumors, including HPV-associated cancers. Comparable in stage, modality (engineered TCR-T), and Singapore/Asia origins — ImmunoScape's VP of Discovery previously held a leadership role at Tessa.

Emerging players

  • Tmunity Therapeutics: Cell therapy developer focused on engineered T cells (CAR-T and TCR-T) for solid tumors and autoimmune disease, founded out of the University of Pennsylvania. Led by Usman Azam (also on ImmunoScape's board) until its wind-down, making it a directly comparable TCR-T solid tumor play.
  • TCR² Therapeutics (now part of Adaptimmune): Developed TRuC-T cell therapies targeting solid tumors using a novel TCR fusion construct. Directly comparable modality (engineered T-cell receptor therapy for solid tumors) and recently combined with Adaptimmune, the leading direct peer.

Broad incumbents

  • Kite Pharma (a Gilead Company): Commercial-stage leader in cell therapy with approved CAR-T products (Yescarta, Tecartus) for hematologic malignancies. A broad incumbent in the engineered T-cell therapy space; Adrian Bot (now on ImmunoScape's board) previously served as Kite's CSO, providing direct strategic adjacency.
  • Novartis: Delivered the first FDA-approved CAR-T therapy (Kymriah) and operates a major Cell and Gene Therapies unit previously headed by Usman Azam, who now sits on ImmunoScape's board. A broad incumbent with the most established cell therapy commercial infrastructure.
  • Bristol Myers Squibb: Developer of Yervoy and Opdivo (immuno-oncology checkpoint inhibitors) and a partner of Immatics for TCR-based therapies. Comparable as a large pharma incumbent pursuing TCR-based solid tumor strategies via partnership and acquisition.
  • AstraZeneca: Developer of Imfinzi (durvalumab), a checkpoint inhibitor broadly used across solid tumor indications. Rachel Humphrey, who led Imfinzi's clinical development, is now an ImmunoScape SAB member — making AstraZeneca a strategically adjacent incumbent in solid tumor immunotherapy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

ImmunoScape social profiles

Digital presence

ImmunoScape financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ImmunoScape leadership team

Management profile

Number of profiles

ImmunoScape funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ImmunoScape M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ImmunoScape

What does ImmunoScape do?

ImmunoScape develops TCR-based cancer immunotherapies through its proprietary Seed-and-Boost platform, which combines engineered TCR-T cells with Immuno-STAT molecules to improve T cell expansion, persistence, and anti-tumor activity in solid tumors. The company's lead program, IS-001, targets WT1-positive solid tumors, and its Deep Immunomics technology underpins antigen and TCR discovery directly from patient-derived immune repertoires. ImmunoScape also extends its technology into partnered programs with pharmaceutical companies, including the CUE-100 series (CUE-102) with Cue Biopharma.

Is ImmunoScape a public or private company?

ImmunoScape is a private company. It is classified as venture growth investor backed and is currently operating.

When was ImmunoScape founded?

ImmunoScape was founded in 2016. It employs 11 to 50 people.

Where is ImmunoScape based?

ImmunoScape is headquartered in Singapore, Singapore, in the Asia region.

How does ImmunoScape make money?

One revenue line is on record: TCR-T Cell Therapy Development.

Who are ImmunoScape's main competitors?

Direct peers on record are Adaptimmune, Immatics, Cue Biopharma and Tessa Therapeutics. Emerging players are Tmunity Therapeutics and TCR² Therapeutics (now part of Adaptimmune). Broad incumbents are Kite Pharma (a Gilead Company), Novartis, Bristol Myers Squibb and AstraZeneca.

Does ImmunoScape have an API?

No public API is recorded for ImmunoScape.

What industry is ImmunoScape in?

ImmunoScape's product category is Cancer Immunotherapy. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAAMAK, Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageArticles from MiNK TherapeuticsImmunoScape and MiNK Therapeutics announced a collaboration to discover and develop next-generation TCR therapies against novel targets in solid tumors. The partnership aims to accelerate TCR-based therapies for T cells, iNKT cells, and other modalities, potentially offering new approaches for diverse cancer indications.citybizImmunoScape Names Peter Olagunju CEO as Cancer Therapy Platform Moves Toward ClinicImmunoScape appointed Peter Olagunju as CEO to advance its Seed-and-Boost TCR-based cancer immunotherapy platform into clinical development. Olagunju brings over 20 years of experience, including work on seven commercialized therapies. The company will move its platform toward clinical execution with partners.Business Wire BlogImmunoScape Appoints Peter Olagunju as Chief Executive OfficerImmunoScape appointed Peter Olagunju as CEO to advance its Seed and Boost TCR-based cancer immunotherapy platform into the clinic. Olagunju brings over 20 years of experience, including leading a Catalio Capital-backed company through a $14 million seed financing. He will work with partners to move the platform into clinical trials.FinancialContent Business PageImmunoScape Appoints Peter Olagunju as Chief Executive OfficerImmunoScape appointed Peter Olagunju as CEO to guide its Seed and Boost TCR-based cancer immunotherapy platform into the clinic. Olagunju brings over 20 years of experience, including seven approved products, and previously led a Catalio Capital-backed oncology company. He will work with partners to advance the platform.BioSpaceImmunoScape Appoints Peter Olagunju as Chief Executive OfficerImmunoScape appointed Peter Olagunju as CEO to advance its Seed and Boost TCR-based cancer immunotherapy platform into the clinic. Olagunju brings over 20 years of experience, including leading a Catalio Capital-backed company through a $14 million seed financing and a corporate transaction. He will work with partners to move the platform into the clinic.MorningstarImmunoScape Appoints Peter Olagunju as Chief Executive OfficerImmunoScape appointed Peter Olagunju as CEO to guide its TCR-based cancer immunotherapy platform toward the clinic. Olagunju brings over 20 years of experience, including leading a Catalio Capital-backed company through a $14 million seed round. He will work with partners to advance the platform into clinical trials.BioSpaceImmunoScape Presents Data on Significant, Selective In-Vivo Expansion of Cell Therapy Product at AACR Annual MeetingImmunoScape presented preclinical data at the AACR Annual Meeting 2026 demonstrating the effectiveness of its Seed and Boost platform in expanding tumor-specific T cells and improving survival in animal models of ovarian and pancreatic cancer. The platform achieved 100% survival in a high tumor burden ovarian cancer model and demonstrated significant tumor infiltration and T-cell expansion, supporting its progression towards first-in-human trials.Pulse 2.0ImmunoScape Signs Clinical Trial MOU With U.S. Cancer Center And Secures Strategic Investment From Leonardo DiCaprioImmunoScape signed a clinical trial MOU with a U.S. cancer center and secured investment from Leonardo DiCaprio. The trial targets WT1-positive solid tumors, including ovarian and pancreatic cancers, with dosing expected to begin in September 2026.BioSpaceImmunoScape Announces Memorandum of Understanding for Clinical Trial with Premier U.S. Cancer CenterImmunoScape Pte. Ltd., a Singapore-based clinical-stage biotechnology company developing TCR-based cancer immunotherapies, announced the execution of a Memorandum of Understanding with a premier NCI-designated Comprehensive Cancer Center in the United States to launch an investigator-initiated clinical trial targeting WT1 positive solid tumors including ovarian, mesothelioma, pancreatic, and colorectal cancers. The trial, leveraging ImmunoScape's 'Seed and Boost' platform, is scheduled to dose its first patients by September 2026. Concurrently, the company announced a strategic investment from actor Leonardo DiCaprio, who cited the urgency for novel cancer interventions as motivation for supporting the platform's development.Business Wire BlogImmunoScape Announces Memorandum of Understanding for Clinical Trial with Premier U.S. Cancer CenterImmunoScape Pte. Ltd. announced a Memorandum of Understanding with an NCI-designated Comprehensive Cancer Center in the United States to launch an investigator-initiated clinical trial for its "Seed and Boost" TCR-based immunotherapy platform targeting WT1 positive solid tumors, including ovarian, mesothelioma, pancreatic, and colorectal cancers, with first patient dosing expected by September 2026. The company simultaneously announced a strategic investment from Leonardo DiCaprio and that its scientists will present at the AACR Annual Meeting in April 2026. The Phase 1 trial will test a differentiated approach combining autologous T-cells engineered with a high-affinity WT1 TCR and an Immuno-STAT fusion protein designed to selectively expand and activate the targeted T-cells.